Lung Cancer News and Research

Latest Lung Cancer News and Research

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

New health initiative focuses on environmentally-associated cancers

The Barbara Ann Karmanos Cancer Institute, in cooperation with Blue Cross Blue Shield of Michigan (BCBSM), will launch a targeted health initiative in January 2010 focused on environmentally-associated cancers.

22 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

Herrick Foundation's $3M grant for cancer research

The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.

21 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

24 Hour Data to support breast cancer awareness, to donate 5% of its October sales to NBCF

24 Hour Data today announced its support for Breast Cancer Awareness Month. In an effort to raise awareness about the importance of early detection of breast cancer, the Dallas-based company will donate 5% of its October sales to the National Breast Cancer Foundation, Inc. (NBCF).

19 Oct 2009

Elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws: IOM

A landmark report released today by the Institute of Medicine provides powerful new evidence that elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws. The IOM report concludes smoke-free laws reduce the number of heart attacks and save lives. The report also confirms that there is conclusive scientific evidence that secondhand smoke causes heart disease, including heart attacks, and finds there is compelling evidence that even relatively brief exposure to secondhand smoke can lead to a heart attack.

19 Oct 2009

NCCN program on Discovery Health Channel profiles patients battling lung cancer

Lung cancer is the second most common cancer and leading cause of cancer-related deaths in both men and women. Although tobacco use is the strongest known risk factor for lung cancer, many people who never smoked also develop the disease.

19 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

ADI and CeTeCancer collaborate for research project

Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer -- a Chilean-based research laboratory -- to validate the effectiveness of Radient Pharmaceuticals' Onko-Sure™ in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.

15 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

Lung Cancer News and Research

Latest Lung Cancer News and Research

Celgene announces fiscal 2009 third-quarter results

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

New health initiative focuses on environmentally-associated cancers

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Herrick Foundation's $3M grant for cancer research

New tools needed to identify men and women at risk for the most aggressive cancers

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

ImmunoCellular Therapeutics files a provisional patent application

24 Hour Data to support breast cancer awareness, to donate 5% of its October sales to NBCF

Elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws: IOM

NCCN program on Discovery Health Channel profiles patients battling lung cancer

Prometheus Laboratories introduces three new cancer diagnostic products

ADI and CeTeCancer collaborate for research project

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

EMEA grants ArQule's ARQ 197 orphan drug designation

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Lung Cancer News and Research

Latest Lung Cancer News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in